NASDAQ:PHIO

Phio Pharmaceuticals Stock Forecast, Price & News

$1.82

-0.02 (-1.09 %)

(As of 07/29/2021 12:00 AM ET)

Add

Compare

Today's Range

$1.80

▼

$1.85

50-Day Range

$1.78

▼

$2.42

52-Week Range

$1.72

▼

$4.36

Volume67,612 shs

Average Volume985,157 shs

Market Capitalization$24.63 million

P/E RatioN/A

Dividend YieldN/A

Beta2.22

30 days | 90 days | 365 days | Advanced Chart

Receive PHIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Phio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

-$0.26 Earnings Per Share Expected for Phio Pharmaceuticals Corp. (NASDAQ:PHIO) This Quarter
July 26, 2021 | americanbankingnews.com

Phio Pharmaceuticals Scheduled to Participate in a Fireside Chat with H.C. Wainwright on July 12th
July 7, 2021 | finance.yahoo.com

Phio Pharmaceuticals Reschedules Fireside Chat Hosted by H.C. Wainwright for July 12th
June 22, 2021 | finance.yahoo.com

Is Phio Pharmaceuticals Corp. (PHIO) A Good Stock To Buy?
June 14, 2021 | finance.yahoo.com

Phio Pharmaceuticals Scheduled to Participate in Two Upcoming Investor Events in June
June 14, 2021 | finance.yahoo.com

Phio Pharmaceuticals Presents New In Vivo Data at the 2021 ASCO Annual Meeting Showing Dual-Targeting INTASYL Offers Increased Efficacy and Safety Potential Over Other Therapeutic Approaches
June 4, 2021 | finance.yahoo.com

Phio Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
May 14, 2021 | finance.yahoo.com

Phio Pharma's PH-762 Shows Encouraging Antitumor Efficacy In Preclinical Studies
May 11, 2021 | finance.yahoo.com

Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly Enhanced Antitumor Efficacy of HER2-Targeted CAR-T Cells
May 11, 2021 | finance.yahoo.com

PHIO - Two Upcoming New Data Releases (1 At ASCO) Will Demonstrate That INTASYL Oncology Platform Could Be Game-Changer In The Fight Against Cancer
May 7, 2021 | seekingalpha.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PHIO
Previous Symbol
CUSIPN/A
CIKN/A
Webphiopharma.com
Phone(508) 767-3861
Employees10
Year FoundedN/A

Sales & Book Value

Annual Sales$20,000.00
Price / Sales1,231.59
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.92 per share
Price / Book1.98

Profitability

EPS (Most Recent Fiscal Year)($1.92)
Net Income$-8,790,000.00
Net MarginsN/A
Return on Equity-50.77%
Return on Assets-44.75%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares13,534,000
Market Cap$24.63 million
Next Earnings Date8/11/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.49 out of 5 stars

Medical Sector

960th out of 2,214 stocks

Pharmaceutical Preparations Industry

462nd out of 869 stocks

3.5 Analyst's Opinion

Consensus Rating
Phio Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, Phio Pharmaceuticals has a forecasted upside of 229.7% from its current price of $1.82.
Amount of Analyst Coverage
Phio Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

3.3 Community Rank

Outperform Votes
Phio Pharmaceuticals has received 31 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Phio Pharmaceuticals has received 16 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Phio Pharmaceuticals has received 65.96% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Phio Pharmaceuticals and other stocks. Vote “Outperform” if you believe PHIO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PHIO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Phio Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Phio Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Phio Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.30% of the stock of Phio Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 3.70% of the stock of Phio Pharmaceuticals is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Phio Pharmaceuticals are expected to grow in the coming year, from ($1.10) to $1.00 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Phio Pharmaceuticals is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Phio Pharmaceuticals is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Phio Pharmaceuticals has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Phio Pharmaceuticals (NASDAQ:PHIO) Frequently Asked Questions

Is Phio Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Phio Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Phio Pharmaceuticals stock.
View analyst ratings for Phio Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Phio Pharmaceuticals?

Wall Street analysts have given Phio Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Phio Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Phio Pharmaceuticals?

Phio Pharmaceuticals saw a decline in short interest in the month of June. As of June 15th, there was short interest totaling 1,140,000 shares, a decline of 26.5% from the May 31st total of 1,550,000 shares. Based on an average daily volume of 860,900 shares, the days-to-cover ratio is currently 1.3 days. Approximately 8.6% of the company's stock are short sold.
View Phio Pharmaceuticals' Short Interest.

When is Phio Pharmaceuticals' next earnings date?

Phio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Phio Pharmaceuticals.

How were Phio Pharmaceuticals' earnings last quarter?

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) announced its quarterly earnings results on Thursday, May, 13th. The company reported ($0.32) EPS for the quarter.
View Phio Pharmaceuticals' earnings history.

How has Phio Pharmaceuticals' stock price been impacted by COVID-19?

Phio Pharmaceuticals' stock was trading at $2.77 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PHIO stock has decreased by 34.3% and is now trading at $1.82.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for PHIO?

1 brokerages have issued 1 year price targets for Phio Pharmaceuticals' shares. Their forecasts range from $6.00 to $6.00. On average, they anticipate Phio Pharmaceuticals' stock price to reach $6.00 in the next year. This suggests a possible upside of 229.7% from the stock's current price.
View analysts' price targets for Phio Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Phio Pharmaceuticals' key executives?

Phio Pharmaceuticals' management team includes the following people:

Gerrit Dispersyn, President, Chief Executive Officer & Director
James Cardia, Vice President-Business Operations
Caitlin Kontulis, Secretary, VP-Finance & Administration
Simon Fricker, Vice President-Research

Who are some of Phio Pharmaceuticals' key competitors?

Some companies that are related to Phio Pharmaceuticals include Processa Pharmaceuticals (PCSA), Gain Therapeutics (GANX), IMARA (IMRA), Yumanity Therapeutics (YMTX), Acasti Pharma (ACST), Aileron Therapeutics (ALRN), Rezolute (RZLTD), Rezolute (RZLT), Aprea Therapeutics (APRE), Eledon Pharmaceuticals (ELDN), Moleculin Biotech (MBRX), Evofem Biosciences (EVFM), Lotus Pharmaceuticals (LTUS), Entasis Therapeutics (ETTX) and Liminal BioSciences (LMNL).
View all of PHIO's competitors.

What other stocks do shareholders of Phio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phio Pharmaceuticals investors own include DURECT (DRRX), CymaBay Therapeutics (CBAY), Ocugen (OCGN), Akero Therapeutics (AKRO), Ampio Pharmaceuticals (AMPE), Boxlight (BOXL), Evofem Biosciences (EVFM), Fulcrum Therapeutics (FULC), Jaguar Health (JAGX) and Milestone Pharmaceuticals (MIST).

What is Phio Pharmaceuticals' stock symbol?

Phio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHIO."

How do I buy shares of Phio Pharmaceuticals?

Shares of PHIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Phio Pharmaceuticals' stock price today?

One share of PHIO stock can currently be purchased for approximately $1.82.

How much money does Phio Pharmaceuticals make?

Phio Pharmaceuticals has a market capitalization of $24.63 million and generates $20,000.00 in revenue each year. The company earns $-8,790,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis.

How many employees does Phio Pharmaceuticals have?

Phio Pharmaceuticals employs 10 workers across the globe.

What is Phio Pharmaceuticals' official website?

The official website for Phio Pharmaceuticals is phiopharma.com.

Where are Phio Pharmaceuticals' headquarters?

Phio Pharmaceuticals is headquartered at 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752.

How can I contact Phio Pharmaceuticals?

Phio Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The company can be reached via phone at (508) 767-3861 or via email at [email protected]

This page was last updated on 7/30/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here